Roche & Zealand Pharma

Roche: As the parent company of F. Hoffmann-La Roche — Genentech, Roche benefits from the positive clinical trial results of enicepatide and petrelintide, which enhance its overall pharmaceutical pipeline and potential for future revenue in the obesity and diabetes markets.

Zealand Pharma: Zealand Pharma is presenting Phase 2 ZUPREME-1 data on petrelintide, a key drug candidate in its obesity and metabolic health pipeline, at a significant scientific conference. This presentation could enhance its reputation and potentially its stock value if the data is well-received.